Gastrointestinal and Renal Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFEGUARD Trial

被引：0
|
作者：
Mraz, Milos
Klouckova, Jana
Kavalkova, Petra
Trachta, Pavel
Krizova, Jarmila
Kosak, Mikulas
Kurzova, Ivana
Kocna, Petr
Haluzik, Martin
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1088-P
引用
收藏
页码：A284 / A284
页数：1
相关论文
共 50 条
  • [1] Cardiovascular Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFE-GUARD Trial
    Mraz, Milos
    Chytilova, Eva
    Klouckova, Jana
    Trachta, Pavel
    Skrha, Jan, Jr.
    Krizova, Jarmila
    Petrak, Ondrej
    Krupicka, Jan
    Tuka, Vladimir
    Kudlicka, Jaroslav
    Kratka, Zuzana
    Dostalova, Gabriela
    Malik, Jan
    Haluzik, Martin
    DIABETES, 2016, 65 : A284 - A284
  • [2] The neuroprotective efficacy of the DPP-4 inhibitor linagliptin against stroke is not mediated by GLP-1 receptor activation
    Darsalia, V.
    Larsson, M.
    Nathanson, D.
    Drucker, D. J.
    Nystrom, T.
    Klein, T.
    Patrone, C.
    DIABETOLOGIA, 2015, 58 : S35 - S35
  • [3] The DPP-4 Inhibitor Linagliptin Improves Cardiac Function in GLP-1 Receptor Knockout Mice with Hypertrophic Heart Failure
    Batchu, Sri N.
    Kabir, Golam
    Klein, Thomas
    Connelly, Kim A.
    DIABETES, 2016, 65 : A127 - A127
  • [4] DPP-4 inhibitors and GLP-1 receptor agonists. Cardiovascular effects
    Nauck, M. A.
    El Aziz, M. S. Abd
    Meier, J. J.
    DIABETOLOGE, 2016, 12 (03): : 184 - +
  • [5] The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose
    Salheen, S. M.
    Panchapakesan, U.
    Pollock, C. A.
    Woodman, O. L.
    PHARMACOLOGICAL RESEARCH, 2015, 94 : 26 - 33
  • [6] Acute Renal Effects of GLP-1 Receptor Agonist Exenatide in Healthy Overweight Males
    Muskiet, Marcel H.
    Tonneijck, Lennart
    Smits, Mark M.
    Joles, Jaap A.
    Kramer, Mark H.
    Diamant, Michaela
    Van Raalte, Daniel H.
    DIABETES, 2015, 64 : A153 - A153
  • [7] Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
    Fadini, Gian Paolo
    Avogaro, Angelo
    VASCULAR PHARMACOLOGY, 2011, 55 (1-3) : 10 - 16
  • [8] GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
    Ahrén, B
    Schmitz, O
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 867 - 876
  • [9] The DPP-4 Inhibitor Linagliptin Restores β-Cell Function and Survival in Human Isolated Islets Through GLP-1 Stabilization
    Shah, Payal
    Ardestani, Amin
    Dharmadhikari, Gitanjali
    Laue, Svenja
    Schumann, Desiree M.
    Kerr-Conte, Julie
    Pattou, Francois
    Klein, Thomas
    Maedler, Kathrin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (07): : E1163 - E1172
  • [10] Renal Effects of 12-Week GLP-1 Receptor Agonist Liraglutide or DPP-4 Inhibitor Sitagliptin Treatment in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Diamant, Michaela
    Joles, Jaap A.
    Van Raalte, Daniel H.
    DIABETES, 2016, 65 : A140 - A140
12345